Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPItrue: Capivasertib+Fulvestrant in HR+/HER2- Advanced Breast Cancer
NCT06635447Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of capivasertib in breast cancer (2 cohorts), sponsored by AstraZeneca. Primary endpoint: Time to first subsequent treatment at 2 years. Started Sep 2024; status: active, not recruiting.
02
Drugs
capivasertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06635447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06635447.